In Japan, drug quality audit reports are generally not publicly available. The Pharmaceutical and Medical Devices Agency (PMDA) oversees drug safety and quality, but detailed audit reports are typically confidential. However, summary information and inspection outcomes may be shared with the public to ensure transparency and maintain trust in the regulatory process.